Introduction
Liver cirrhosis is caused by unrelenting hepatocellular death and regeneration in association with activation of liver fibrogenesis as result of persistent exposure of the liver to toxic, infectious, immunologic or metabolic insults. [1] [2] [3] Progression of liver cirrhosis leads to hepatocellular failure and portal hypertension. These two pathophysiological disturbances determine a characteristic clinical syndrome that includes protein-calorie malnutrition, ascites formation, bleeding and endocrine alterations such as hypogonadism. Orthotopic liver transplantation is the only curative treatment for patients with advanced stages of the disease. Therefore, therapies aimed at halting the progression of liver cirrhosis are much needed.
Insulin-like growth factor I (IGF-I) is an anabolic hormone synthesized in various organs upon stimulation with growth hormone. 4 Serum IGF-I is mostly of hepatic origin 5, 6 and circulates bound to a set of binding proteins (IGF-binding proteins (IGFBPs)), which affect the biological activity of the hormone. 4, 7, 8 The liver is the main source of IGFBPs, in particular of IGF-binding protein 3 (IGFBP3), whose synthesis is stimulated by IGF-I and is the major binder for this hormone. 7 Previous data from our laboratory have shown that treatment of experimental liver cirrhosis with recombinant IGF-I (rIGF-I) promotes weight gain, nitrogen retention, intestinal absorption of nutrients, osteopenia and hypogonadism. 9 In addition, IGF-I reduces inflammation, liver cell damage and decreases fibrogenesis in CCl 4 -treated rats. 10, 11 In a recent controlled pilot clinical trial, administration of rIGF-I for 4 months induced a decrease of Child-Pugh score in alcoholic cirrhosis. 12 Results from this trial suggested that the appropriate replacement daily dose of IGF-I in advanced cirrhosis is about 100 mg/ kg given continuously. However, because of the high amount of recombinant protein needed per patient, the potential benefit of IGF-I therapy in liver cirrhosis is counterbalanced by the high cost of the treatment.
Hepatic gene transfer may be an alternative to the use of recombinant protein. When the goal of gene therapy is to protect the liver against chronic injury, it should be mandatory the use of long-term expression vectors. Here, we used a recombinant simian virus 40 vector (rSV40) encoding IGF-I to evaluate whether sustained expression of IGF-I within the liver could be efficient in controlling the development of liver cirrhosis in rats subjected to chronic exposure to CCl 4 . Vectors based on rSV40 are replication-deficient, non-oncogenic and poor immunogens and are able to support expression of heterologous genes in the liver. [13] [14] [15] These vectors have proven to be efficient in therapies for conditions such as the Crigler-Najjar syndrome and a 1 -antitrypsin deficiency. 16, 17 In the present work, we show that rSV40 vectors are able to transduce mice liver at least for 7 months and that a rSV40 encoding IGF-I reduces liver cell damage and fibrogenesis and corrects hypogonadism in CCl 4 -treated rats.
Results

Measurement of luciferase expression in mice livers infected with rSV40 vectors
The ability of rSV40 to infect and express a transgene in hepatic cell lines and in the liver has been already shown. [13] [14] [15] [16] [17] To evaluate rSV40-mediated liver expression in mice in a more quantitative manner, rSV40 expression of firefly luciferase was visualized with a charge-couple device (CCD) camera. Luciferase expression in the liver was detected for more than 7 months after a single intravenous injection of recombinant SV40-luciferase virus (rSVLuc) (Figure 1a and b). After this time period, luciferase gene could be amplified by polymerase chain reaction (PCR) in livers from rSVLuc-infected animals when the DNA was obtained from the genomic but not from the episomal fraction (data not shown). This result, together with the fact that several hepatectomies could be performed in mice without loss of hepatic luciferase activity, suggests that rSV40 integrates into the cell genome of infected cells, as has been previously suggested (data not shown). [13] [14] [15] rSVLuc expression was approximately 100-fold lower than the peak expression observed in mice infected with adenovirus or adeno-associated virus expressing luciferase (data not shown). Thus, we tested whether luciferase expression in the liver from rSVLuc vectors could be increased by several means. Liver damage produced by intraperitoneal administration of CCl 4 induced a significant increase (Po0.05) of luciferase expression in the liver at 4 days post-CCl 4 challenge (Figure 1c) , suggesting that expression from rSV40 vectors may be modulated by factors generated during liver regeneration. As IGF-I favors liver regeneration, 18 we analyzed luciferase expression in rSVLuc-infected mice that received rIGF-I or saline by subcutaneous injection. Interestingly, luciferase expression in the liver increased significantly (Po0.05) 48 h after rIGF-I administration (Figure 1c) .
Expression of IGF-I from rSV40
As rSV40 vectors infecting the liver can support longterm transgene expression, which may increase during the regenerative wave that follows liver damage, we decided to construct a rSVIGF-I vector and test its therapeutic efficacy in a model of chronic CCl 4 -induced liver damage in rats. To this aim, rat IGF-I complementary DNA (cDNA) was cloned into a Tag-deleted SV40 vector to obtain the rSVIGF-I genome ( Figure 2a 
Biological and therapeutic effects of rSVIGF-I in rats with CCl 4 -induced cirrhosis
Three groups of rats were subjected to CCl 4 inhalation for 36 weeks and killed. An additional group of four rats, not exposed to the hepatotoxin, was used as a healthy control. The CCl 4 -treated rats were injected intraportally with saline, rSVLuc or rSVIGF-I 1 week before and 20 weeks after initiatiating CCl 4 exposure ( Figure 3a) . As the statistical analysis of the different parameters tested showed no differences between rSVLuc-infected and saline-treated groups, these two groups were considered as a single control cirrhotic group (Ci). PCR analysis demonstrated the persistence and expression of rSV40 vector in the liver for long periods. Thus, at the end of the study we could detect the presence of rSVLuc genomes in rats infected with this virus (Figure 3b ). Also, a significant increase (Po0.001) of liver IGF-I mRNA was detected by quantitative reverse transcriptase-PCR (RT-PCR) in the group of rats treated with rSVIGF-I (Ci+IGF-I) as compared to healthy controls (0.07570.042 and 0.41570.185 in normal and Ci+IGF-I, respectively). However, total serum IGF-I measured by radioimmunoassay (RIA), showed similar values in the three experimental groups at the end of the study (Co ¼ 10827125, Ci ¼ 11507197, Ci+IGF-I ¼ 12027111 ng/ml), probably owing to a compensatory mechanism mediated by growth hormone, which controls both intrahepatic and extrahepatic IGF-I synthesis. 6 Most of the circulating IGF-I function is modulated by IGFBPs. IGFBP3 is the major IGF-I-binding protein in plasma, and its production is increased by IGF-I. A significant increase in IGFBP3 mRNA levels was found in the liver of Ci+IGF-I rats (Ci ¼ 0.08070.031, Ci+IGF-I ¼ 0.17570.064; Po0.005) in agreement with higher intrahepatic IGF-I mRNA values in this group of rats. Similarly, serum IGFBP3 levels detected by Western blot analysis were significantly increased (Po0.01) in the rSVIGF-I-treated group in serum samples collected at the end (Figure 4a and b) or throughout the study (data not shown).
The effect of rSVIGF-I on liver damage and cirrhosis progression was examined. Serum transaminases were increased in Ci rats as compared to normal animals, whereas similar values were found in Ci+IGF-I and in normal rats (Figure 4c and d) . Also, serum bilirubin was increased in the Ci group when compared to healthy controls but bilirubin was normal in Ci+IGF-I animals ( Figure 4e ). Serum albumin levels were similar (a) Healthy male Wistar rats were infected via the portal vein with 10 11 virus particles of rSVLuc, rSVIGF-I or the same volume of saline serum as a negative control. One week after infection, animals were subjected to CCl 4 inhalations twice a week. Once cirrhosis was established at week 14, CCl 4 inhalations were performed weekly. At week 20, rats were given intraportally the same dose of the viral vector or saline. Animals were killed at week 37. (b) Total DNA was extracted from rat livers 37 weeks after infection. Luciferase gene was amplified by nested PCR from healthy rat livers (lanes 1 and 2), mock-infected rat livers (lanes 3 and 4), rSVIGF-I-infected (lanes 5 and 6) or rSVLuc-infected rat livers (lanes 7-9). rSVLuc genome was used as a positive control (+) and water as a negative control (À). Prolonged CCl 4 administration induces liver fibrosis. We found that Ci+IGF-I animals showed a significant reduction of collagen deposition in liver sections when compared to Ci rats, as assessed by both image analysis ( Figure 5A and B) and hepatic hydroxyproline concentration (15.7076.36 and 7.1773.48 mg hydroxyproline/ mg glycine in Ci and Ci+rSVIGF-I groups, respectively; Po0.01). Similar differences in collagen deposition were observed in liver biopsies collected before the second intraportal injection of rSV40 (data not shown). The amount of ascitic fluid in Ci+IGF-I rats (0.270.1 ml) was significantly lower than in the Ci group (2.071.5 ml; Po0.05). As lipid peroxidation products are potent inducers of fibrogenesis, 19 we determined the levels of malondialdehyde (MDA) in the liver in the three experimental groups. In agreement with data mentioned above, we observed a significant reduction (Po0.01) of MDA in the liver in Ci-IGF-I as compared to Ci animals (7.174.1, 3.671.9 and 1.870.4 in Ci, Ci+IGF-I and healthy animals).
Hepatocyte growth factor (HGF) has been demonstrated to display potent antifibrogenic effects. 20 Our group has previously reported that this factor is induced by IGF-I in vivo.
18 Thus, we measured HGF mRNA levels in liver samples in the three experimental groups. As shown in Figure 5C , HGF was markedly upregulated in Ci+IGF-I livers as compared to both Ci and healthy controls (Po0.05).
IGF-I upregulates STAT3a, a factor that exerts potent cytoprotective and anti-inflammatory effects. 21 We found that cirrhotic rats showed, as compared to healthy animals, decreased hepatic levels of STAT3a, whereas STAT3b, a negative regulator of STAT3a, 22 was increased. Interestingly, Ci+IGF-I rats showed normal STAT3a levels, whereas STAT3b was almost undetectable ( Figure 5D) .
A typical feature of liver cirrhosis is hypogonadism. Thus, we evaluated whether rSV40-mediated IGF-I expression in the liver could reverse gonadal impairment in experimental cirrhosis. We found that testis weight was significantly lower in Ci animals than in healthy controls and was similar to normal in Ci+IGF-I rats ( Figure 6A) . Moreover, histological analysis showed a clear reduction in the diameter of the seminiferous tubes and an inhibition of spermatogenesis in Ci rats as compared to normal control or Ci+IGF-I animals ( Figure 6B ).
Discussion
Results in this paper highlight a role for rSV40 vectors in the treatment of chronic liver diseases. Here, we show that these vectors are able to sustain luciferase gene expression in the liver of mice for at least 7 months (Figure 1a and b) and that rSVLuc genome can be detected in rat liver 37 weeks after infection (Figure 3b ). Our data suggest that the long duration of transgene expression appears to be due to the integration of the vector into the cell genome, as has been previously reported by others. [13] [14] [15] Using a CCD camera, we observed increased transgene expression in rSVLuc-infected livers after challenge with CCl 4 (Figure 1c ), hepatectomy (data not shown) or rIGF-I administration (Figure 1c) . Although it still remains to be determined, these results could reflect activation of SV40 promoter during liver damage and regeneration. This increase, together with long-term 
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transgene expression in the liver, suggests that SV40 vectors may be valuable tools for treating conditions with protracted liver damage such as chronic hepatitis and liver cirrhosis. Liver transplantation remains as the only effective therapy for advanced liver disease, but only a minority of patients with end-stage cirrhosis may benefit from this possibility. Thus, there is an urgent need for efficient therapies to prevent the progression of liver disease to liver cirrhosis. Antioxidants, multiple antifibrotic drugs and growth factors such as IGF-I, have proven successful in animals, although only the latter has been tested in humans with promising results. 1, 12 Gene therapy has also been envisioned as an useful tool for the treatment of liver fibrosis. Gene transfer to the liver of HGF using hemagglutinating virus of Japan-liposome hybrid vector reduced liver fibrogenesis in a model of dorsomedial nucleus-induced hepatic damage. 23, 24 Administration of adenoviral vectors encoding activated AKT or transforming growth factor-b (TGF-b) inhibitors has also been shown to induce antifibrogenic effects in experimental models of liver injury. 25, 26 However, these studies were performed using short-term expression vectors that are not appropriate for the clinical management of chronic liver disease. [23] [24] [25] [26] In our work, we tested the efficiency of a rSVIGF-I vector in rats with CCl 4 -induced liver cirrhosis. Our approach was based on the use of a longterm expression vector encoding IGF-I, a factor endowed with hepatoprotective properties and whose hepatic expression is markedly reduced in cirrhotic patients. 12 We found that rats which received rSVIGF-I showed marked reduction of fibrogenesis ( Figure 5A and B) and ascitis formation together with a significant decrease in serum transaminanses and bilirubin levels (Figure 4c and e). This indicates that rSVIGF-I treatment exerted cytoprotective and antifibrogenic effects and was able to protect against the development of liver cirrhosis in rats exposed to liver injury for a prolonged period of time . These findings are in agreement with previous reports using rIGF-I in experimental liver cirrhosis 10 and are also in line with data in IGF-I-transgenic mice challenged with CCl 4 .
18
CCl 4 treatment was chosen because it leads to a hepatic damage that reproduces many of the complications found in human alcoholic cirrhosis. 27 CCl 4 -induced toxicity is mostly mediated by cytochrome P450 2E1 expression in hepatocytes. 28 Cyt P450 expression is under the influence of testicular hormones and growth factors. 29 Thus, IGF-I expression could alter 2E1 levels and therefore CCl 4 -induced toxicity, leading to a misinterpretation of the results. However, we have not observed differences in 2E1 mRNA or protein accumulation in liver samples taken from cirrhotic rats or cirrhotic rats treated with IGF-I at week 20 or at the end of the study (data not shown), indicating that in our model IGF-I does not seem to be affecting 2E1 expression. rSV40 vectors were administered twice; first to healthy rats and later to the same rats once liver cirrhosis was established. Whether the second infection was efficient or not is not known, as the excess of extracellular matrix deposition in the liver of cirrhotic rats could decrease the transduction efficiency of hepatocytes. Further experiments are necessary to asses whether rSV40 can productively infect cirrhotic livers and whether viral vectors expressing higher levels of IGF-I can revert established cirrhosis. We believe that even in the case that only the first rSVIGF-I administration would have been productive, the results obtained in this work are of clinical relevance. Liver cirrhosis development occurs as a result of long-term exposure to liver damage. Some persistent liver insults, such as viral infections, are unavoidable and therefore liver cirrhosis can be predicted. In these cases, treatment with rSVIGF-I vectors could delay cirrhosis progression.
Activated hepatic stellate cells (HSCs) are the main source of the extracellular matrix and matrix metalloproteases, which clear collagen and enhance matrix remodeling in liver fibrosis.
1-3 HSC activation is mainly due to the presence of proinflammatory cytokines, for example, TGF-b.
1 IGF-I acts within the liver in an autocrine/paracrine manner to induce potent antifibrogenic factors such as HGF. 18 In agreement with these findings, we observed increased hepatic expression of HGF in rSVIGF-I-treated cirrhotic rats ( Figure 5C ). As HGF not only inhibits fibrogenesis but it also displays hepatoprotective activities and promotes hepatocellular regeneration, it seems possible that part of the therapeutic properties of rSVIGF-I might be due to the induction of HGF in the liver.
STAT3a is an essential factor in the defense of the liver and other organs against inflammatory damage, 21 whereas STAT3b is a negative regulator of STAT3a. 22 A decrease of hepatic STAT3a expression was found in chronic liver disease in correlation with the intensity of hepatocellular damage. 22 In the present paper, we also observed a decrease in STAT3a along with upregulation of STAT3b in cirrhotic livers. Importantly, these changes were absent in the Ci+IGF-I group, suggesting that the modulation of STAT3 expression by IGF-I may be involved in the beneficial effect of rSVIGF-I therapy.
In rSVIGF-I-treated rats, we found that serum IGF-I remained unchanged, whereas serum IGFBP3 increased significantly (Figure 4a and b) . This could represent higher levels of IGF-I bound to IGFBP3 than to other IGFBPs and suggests a paracrine effect of IGF-I expressed within the liver from the rSVIGF-I vector. The lack of increase of systemic IGF-I in association with increased IGFBP3 may represent an advantage of IGF-I gene therapy, as it has been shown that there is a greater risk of breast, prostate, lung and colorectal cancer in patients with high IGF-I and low IGFBP3 in serum. 30, 31 It should be noted that cirrhotic rats treated with rSVIGF-I exhibited normal testicular size and histology in sharp contrast to control cirrhotic rats, which exhibited intense testicular atrophy and disturbed spermatogenesis. Hypogonadism could be a consequence of decreased IGF-I bioavailability during cirrhosis 9 as IGF-I stimulates testosterone synthesis, spermatogenesis and activates Sertoly cell proliferation. Hypogonadism was not detected in the rSVIGF-I-infected animals ( Figure  6B ). As we could not detect rSV40 vectors in testis (data not shown) and serum IGF-I levels were similar in all experimental groups, the trophic effect of rSVIGF-I on the testis may reflect the overall improvement in liver function in animals treated with this vector. 9 It has been shown that porto-systemic shunting may cause hypogonadism as a result of estrogens bypassing the liver. 32 Although portacaval shunting was not directly analyzed, it seems possible that lower shunting and improved liver SV40 expressing IGF-I reduces liver cirrhosis M Vera et al metabolism of estrogens in these animals may contribute to the correction of the hypogonadism.
In summary, we have shown that rSV40 vectors can direct long-term transgene expression in the liver and that the expression level is increased in situations of hepatic damage. Furthermore, this work supports the hypothesis that gene therapy allowing sustained hepatic expression of IGF-I is an efficient strategy to halt the progression of liver cirrhosis.
Materials and methods
Cell lines
Simian kidney COS-1 cells were obtained from the ECACC (Wiltshire, UK) and fibroblast 3T3 cells from the ATCC (Manassas, VA, USA). Cell lines were cultured as described.
33 3T3 cells were grown in plates pretreated with poly-L-Lys (Sigma, St Louis, MO, USA).
Recombinant SV40 viruses
rSVLuc was produced and titrated as described. 34 To generate a rSV40 virus with the rat IGF-I gene (rSVIGF-I), rat IGF-I cDNA was digested with BglII and XbaI from pX21 plasmid (kindly donated by Dr Novo) and cloned into the same restriction sites of pSL-4pL. 34 rSVIGF-I vectors were produced and titrated to 1 Â 10 11 virus particles/ml by real-time quantitative PCR. 34 Contamination of the rSVIGF-I stocks by revertant wild-type SV40 was not detected (data not shown). 34 
IGF-I analysis
A total of 3.5 Â 10 6 COS-1 cells were infected for 3 days with rSVIGF-I or rSVLuc. Then, the supernatant was concentrated 15 times by lyophilization and 50 ml were used to quantify IGF-I by a RIA assay (DSL, Webster, TX, USA). The activity of IGF-I was measured in 3T3 cells serum-starved for 24 h and treated for 20 min with 100 ml of the supernatant of COS-1 cells infected as indicated above. After stimulation, 3T3 cells were lysed and AKT phosphorylation was measured by Western blot. 35 A Western blot against an endogenous protein served to ensure equal loading.
Mice
All experiments with animals were performed following guidelines from the institutional ethical commission. Female Balb/C mice (20 g) were infected using the lateral tail vein or the portal vein with 1 Â 10 9 viral particles of rSVLuc. Intraportal-infected mice were subjected to intraperitoneal administration of 1 ml/g of body weight of CCl 4 (Merck, Darmstadt, Germany) dissolved to 200 ml with olive oil or to subcutaneous administration of 2 ng/ 100 g of body weight of rIGF-I (Chiron Corporation, Emeryville, CA, USA) in two bolus injections. 36 Rats rSV40 vectors were injected intraportally in male Wistar rats (180-200 g). Eight rats were injected with 1 Â 10 11 viral particles of rSVIGF-I, six rats with the same amount of rSVLuc and six rats were mock infected. One week after virus injection all rats were subjected to phenobarbital administration (luminal) and CCl 4 (Merck) inhalation twice a week for 14 weeks and once a week until the end of the study. 27 At week 20, rats were reinfected with the same viral dose. Four healthy non-infected control rats were studied in parallel. Blood was collected from the retro-orbital plexus every other week. Rats were killed after 37 weeks of treatment, testes were weighed and subjected to microscopic analysis and livers were processed for histology and DNA, RNA and protein analysis.
Measurement of luciferase activity
Luciferase activity was detected and quantified with a CCD camera (Xenogen, Alameda, CA, USA) in mice, 5 min after an intraperitoneal injection of 3 mg of luciferine substrate and anesthetics. 37 
Serum analytical methods
Serum transaminases (alanine aminotransferase and aspartate), albumin and bilirubin, were measured (ABX diagnostics, Montpellier, France) in a Hitachi autoanalyzer (Roche, Mannheim, Germany). IGFBP3 concentration was determined in total rat serum by Western blot analysis 38 developed with 125 I-labelled rat IGF-I (DSL) Oligo sequences, annealing temperatures (Tm) and elongation times at 721C are indicated. GADPH  GATGGTGAAGGTCGGTGTG  CTTCCACGATGCCAAAGTTG  3  68  87  IGF-I  TTCAGTTCGTGTGTGGACCAAGG  GAAGTCCCAGCCCCTATCGACAC  2  63  87  IGFBP3  CCTCCGAGTCTAAGCGGGAGAC  GCATTGCCTCAGCGTGCAGAG  2  63  86  HGF  AGGGAATCCTCTCGTTCCTTGG  GAGGCGAGGCGAAACGCAAAC  3  62  83 Abbreviations: GADPH, glyceraldehyde-3-phosphate dehydrogenase; HGF, hepatocyte growth factor; IGF-I, insulin-like growth factor-I; IGFBP3, IGF-binding protein 3; PCR, polymerase chain reaction. Primer sequences, Cl 2 Mg concentrations used, annealing temperatures (Tm) and fluorescence temperatures (Tf) are indicated.
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Determinations in liver samples
Total liver DNA was extracted (DNeasy Tissue Kit, Qiagen) and luciferase gene was amplified by nested PCR (Table 1) . Liver RNA was extracted 39 and IGF-I, IGFBP3 and HGF expression quantified by real-time PCR (Roche) and normalized to glyceraldehyde-3-phosphate dehydrogenase (GADPH) expression (Table 2 ). STAT3 was measured by Western blot and normalized to GADPH expression as described. 22 Hydroxyproline was measured colorimetrically from hydrolyzed liver tissue 40 and normalized to the amount of glycine determined in the same samples with the ninhydrin reaction. Liver lipid peroxidation was quantified by measuring MDA colorimetrically. 10 Values of enzyme activities were normalized to the amount of liver protein measured by Bradford. Samples of liver and testis were fixed in 4% paraformaldehyde, paraffin embedded and stained with hematoxylin-eosin. Liver collagen content was assessed by Sirius red staining and scored by imaging analysis (AnalySIS 3.1, Soft Imaging System, Mü nster, Germany). 41 
Statistical analysis
The normality of quantitative variables was assessed with Kolmogorov-Smirnov var. Lilliefors and ShapiroWilks tests. When necessary, homoscedasticity was evaluated with the Levene test on the means. Luciferase activity data were logarithmically transformed before analysis, and compared with analysis of variance (ANOVA) or t-test. Time course data groups were compared with repeated ANOVA test and Tukey-B or non-orthogonal contrasts with Sidak adjustment as post hoc comparisons. When the normality could not be proven, Kruskal-Wallis tests were used to evaluate global differences, and multiple Bonferroni-corrected Mann-Whitney U-tests were used as post hoc comparisons. Control groups that were proven undistinguishable were pooled for increased sensitivity. Differences were deemed significant for a real alpha of 0.05. All statistical analyses were carried out with SPSS v11.0 (SPSS Inc., Chicago, IL, USA).
